Prognostic impact of the tumor immune microenvironment in pulmonary pleomorphic carcinoma.


Journal

Lung cancer (Amsterdam, Netherlands)
ISSN: 1872-8332
Titre abrégé: Lung Cancer
Pays: Ireland
ID NLM: 8800805

Informations de publication

Date de publication:
03 2021
Historique:
received: 02 10 2020
revised: 24 12 2020
accepted: 04 01 2021
pubmed: 18 1 2021
medline: 22 6 2021
entrez: 17 1 2021
Statut: ppublish

Résumé

Pulmonary pleomorphic carcinoma (PC) is a rare non-small cell lung carcinoma (NSCLC) and is characterized by sarcomatoid and NSCLC components. This study aimed to characterize the association between immune microenvironmental factors and clinicopathological characteristics of PC. Eighty consecutive PC patients who had undergone complete surgical resection were enrolled. We calculated the immunohistochemical staining scores for E-cadherin, vimentin, programmed death ligand 1 (PD-L1), and carbonic anhydrase IX in cancer cells and counted the numbers of CD204-positive tumor-associated macrophages (TAMs) and Foxp3-, CD8-, and CD20-positive tumor-infiltrating lymphocytes (TILs). We also examined the association between these scores and the prognostic outcomes. The staining score for PD-L1 in cancer cells and the number of CD204-positive TAMs in the sarcomatoid component were significantly higher than those in the NSCLC component; E-cadherin score in the sarcomatoid component was significantly lower. Patients with high PD-L1 expression in the NSCLC component had significantly longer overall survival (OS) and recurrence-free survival (RFS) than those with low PD-L1 expression in the NSCLC component (OS: p = 0.001, RFS: p = 0.038). Multivariate analysis revealed that high PD-L1 expression in the NSCLC component was an independent favorable prognostic factor for OS (p = 0.018), whereas high PD-L1 expression in the sarcomatoid component was not. The number of CD8-positive TILs was significantly higher in the high PD-L1 expression group than in the low expression group (NSCLC components: p < 0.001). High PD-L1 expression in the NSCLC component may be associated with a favorable prognostic value in pulmonary PC.

Identifiants

pubmed: 33454518
pii: S0169-5002(21)00012-X
doi: 10.1016/j.lungcan.2021.01.007
pii:
doi:

Substances chimiques

B7-H1 Antigen 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

56-65

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Ryosuke Amemiya (R)

Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan; Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan; Departments of Surgery, Tokyo Medical University, Tokyo, Japan.

Tomohiro Miyoshi (T)

Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

Keiju Aokage (K)

Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

Jun Suzuki (J)

Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan; Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

Hironobu Hoshino (H)

Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan; Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

Hibiki Udagawa (H)

Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Kenta Tane (K)

Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

Masato Sugano (M)

Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.

Motohiro Kojima (M)

Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.

Satoshi Fujii (S)

Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.

Takeshi Kuwata (T)

Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.

Atsushi Ochiai (A)

Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.

Koichi Goto (K)

Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Norihiko Ikeda (N)

Departments of Surgery, Tokyo Medical University, Tokyo, Japan.

Masahiro Tsuboi (M)

Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

Genichiro Ishii (G)

Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan. Electronic address: gishii@east.ncc.go.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH